Compare Agilent Technologies Inc (A) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Starbucks Corp — how do they compare? Agilent Technologies Inc trades at $149.59 (market cap $42.00B), while Starbucks Corp trades at $106.03 (market cap $119.30B). The key difference: Starbucks Corp is far larger — about 2.8× Agilent Technologies Inc's market cap, and Starbucks Corp pays the higher dividend (2.37%). Which is the better fit depends on your goals.
| A | SBUX | |
|---|---|---|
Market Cap | $42.00B | $119.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $108.37 |
52-Week Low | $110.24 | $78.46 |
Enterprise Value | $43.55B | $138.12B |
Dividend Yield | 0.69% | 2.37% |
Volume | — | 7,493,833 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Starbucks (SBUX) trades at $105.58, up 0.4% today, with a bullish technical signal and recent earnings beats driving momentum. The stock shows strong fundamental recovery with Q2 2026 EPS of $0.85 beating estimates by 29%, while revenue growth and margin expansion support a raised 2026 outlook. Analyst consensus is split evenly between Buy and Hold, with a $113.60 price target suggesting modest upside from current levels.
The outlook is positive as operational improvements and traffic recovery underpin earnings growth, but high valuation multiples (P/E 61) and competitive pressures pose risks. Investor sentiment is cautiously optimistic, focusing on sustained execution of the turnaround strategy amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
